Assessment of Androgen Receptor Expression in Endometrial Carcinoma via Immunohistochemistry and Its Clinical Implications
-
By
-
Alaa saad Abd elhamid Mohamed
-
Heba Ashraf Hosni
-
Maram Salaheldeen Mahmoud
-
Alzahraa Abdelmoktader Mohammed
-
September 26, 2026
Clinical Scorecard: Assessment of Androgen Receptor Expression in Endometrial Carcinoma via Immunohistochemistry and Its Clinical Implications
At a Glance
| Category | Detail |
|---|
| Condition | Endometrial Carcinoma |
| Key Mechanisms | Androgen receptor signaling may have tumor-suppressive activity and can inhibit tumor growth. |
| Target Population | Patients with endometrioid or serous endometrial carcinoma |
| Care Setting | Retrospective cohort study in a clinical pathology context |
Key Highlights
- Endometrial carcinoma is the most commonly diagnosed gynecological malignancy in developed countries.
- AR expression may correlate with tumor differentiation, advanced FIGO stage, and high tumor grade.
- The study utilized immunohistochemical staining to evaluate AR expression in endometrial tissue specimens.
Guideline-Based Recommendations
Diagnosis
- Utilize WHO diagnostic criteria for categorizing endometrial carcinoma subtypes.
Management
- Integrate genomic markers with conventional anatomical and histopathological findings for clinical management.
Monitoring & Follow-up
- Assess AR expression status in clinical specimens to clarify its diagnostic utility.
Risks
- Increased endogenous testosterone and bioavailable androgen concentrations may affect the risk profile for endometrial tumors.
Patient & Prescribing Data
Patients undergoing total hysterectomy for endometrioid or serous carcinomas.
AR activation may inhibit EC proliferation and migration.
Clinical Best Practices
- Conduct thorough histopathological evaluation using standard processing and staining protocols.
- Ensure independent assessment of immunohistochemical staining by qualified pathologists.
Related Resources & Content
